Shanghai Bangwin Medical Technology Co., Ltd. has officially announced the successful closure of an angel round financing, raising nearly 100 million yuan. This financing endeavor was spearheaded by Daotong Investment, with Jinding Capital joining as a subsequent investor. The newly acquired funds are earmarked for enhancing production capacity, driving product innovation, and expanding the talented team.

Established in 2019, Bangwin Medical has carved out a niche in the high-end wound closure consumables and surgical device sector, offering products that cater to a diverse range of medical departments. Presently, the market for surgical sutures in China is on an upward trajectory, with high-end products witnessing a significant surge in demand. Despite this growth, over 70% of the high-end market remains under the control of foreign-funded enterprises.

Bangwin Medical distinguishes itself through its unique product offerings, including the groundbreaking Vega® absorbable knotless barbed surgical suture, an innovative triclosan antibacterial suture manufacturing process, and the world's pioneering absorbable self-powering suture (BESTURE). Backed by a robust team, the company has capitalized on centralized procurement opportunities to achieve notable breakthroughs in the domestic market. Furthermore, it has forged a strategic partnership with Medtronic and is steadily making inroads into the international arena.

Investors have expressed bullish sentiments regarding Bangwin Medical's growth prospects. The Chairman of Bangwin Medical articulated that, post-financing, the company will embark on capacity expansion initiatives, expedite the production of its innovative product pipeline, and advance product clinical trials and commercialization efforts. The overarching goal is to emerge as a preeminent benchmark in the domestic wound closure industry.